Egetis Therapeutics (Sweden) Insiders
| EGTX Stock | SEK 5.61 0.21 3.89% |
Egetis Therapeutics employs about 17 people. The company is managed by 10 executives with a total tenure of roughly 40 years, averaging almost 4.0 years of service per executive, having 1.7 employees per reported executive. Breaking down Egetis Therapeutics' management performance can provide insight into the firm performance.
| Torsten Almn Insider Founder |
| Louis Ignarro Insider Founder |
Egetis |
Egetis Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.136) % which means that it has lost $0.136 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2602) %, meaning that it generated substantial loss on money invested by shareholders. Egetis Therapeutics' management efficiency ratios could be used to measure how well Egetis Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Egetis Therapeutics Workforce Comparison
Egetis Therapeutics AB is one of the top stocks in number of employees category among its peers. The total workforce of Biotechnology industry is currently estimated at about 232. Egetis Therapeutics holds roughly 17.0 in number of employees claiming about 7% of stocks in Biotechnology industry.
Egetis Therapeutics Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Egetis Therapeutics Price Series Summation is a cross summation of Egetis Therapeutics price series and its benchmark/peer.
Egetis Therapeutics Notable Stakeholders
An Egetis Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Egetis Therapeutics often face trade-offs trying to please all of them. Egetis Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Egetis Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Torsten Almn | Founder | Profile | |
| Louis Ignarro | Founder | Profile | |
| Rob Towart | Founder | Profile | |
| Associate Brurok | Founder | Profile | |
| Yilmaz Mahshid | Chief Officer | Profile | |
| Ingemar Lundstrm | Founder | Profile | |
| MBA MBA | Chief Officer | Profile | |
| Peter Verwaijen | Global Strategy | Profile | |
| Nicklas Westerholm | Chief Officer | Profile | |
| Karl Hard | Head VP | Profile |
About Egetis Therapeutics Management Performance
The success or failure of an entity such as Egetis Therapeutics often depends on how effective the management is. Egetis Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Egetis management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Egetis management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Egetis Therapeutics AB , a pharmaceutical drug development company, focuses on projects in late-stage development for the treatment of serious rareniche diseases with unmet medical needs in the orphan drug segment. Egetis Therapeutics AB was founded in 2006 and is based in Stockholm, Sweden. Egetis Therapeutics operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 11 people.
Please note, the imprecision that can be found in Egetis Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Egetis Therapeutics AB. Check Egetis Therapeutics' Beneish M Score to see the likelihood of Egetis Therapeutics' management manipulating its earnings.
Egetis Therapeutics Workforce Analysis
Traditionally, organizations such as Egetis Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Egetis Therapeutics within its industry.Egetis Therapeutics Manpower Efficiency
Return on Egetis Therapeutics Manpower
| Revenue Per Employee | 2.2M | |
| Revenue Per Executive | 3.8M | |
| Net Loss Per Employee | 6.1M | |
| Net Loss Per Executive | 10.5M |
Additional Tools for Egetis Stock Analysis
When running Egetis Therapeutics' price analysis, check to measure Egetis Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Egetis Therapeutics is operating at the current time. Most of Egetis Therapeutics' value examination focuses on studying past and present price action to predict the probability of Egetis Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Egetis Therapeutics' price. Additionally, you may evaluate how the addition of Egetis Therapeutics to your portfolios can decrease your overall portfolio volatility.